Strategic Partnerships Leverage Remepy’s ongoing collaboration with Merck KGaA as a blueprint to approach other pharmaceutical companies for co-development and licensing of hybrid drug and digital therapy assets, accelerating market access and expanding pipeline opportunities.

AI Enabled Platform Position the Digital Molecules platform as a scalable, AI-driven companion for pharmaceutical assets, offering personalized digital protocols that can be licensed with drugs to boost efficacy, while emphasizing regulatory readiness and cross-disease applicability.

Reimbursement Strategy Capitalize on the single-prescription Hybrid Drugs concept to address reimbursement hurdles by packaging drug components with AI based digital therapies in a single offering, appealing to payers and regulators.

Multi-Disease Expansion Target large and mid-size pharma looking to diversify across disease areas; Remepy’s multi-indication approach and existing partnerships create a fast path for joint development programs.

Agile Growth Partner Differentiate Remepy as an agile, AI-enabled partner with a proven track record of industry collaboration, offering a compelling option for co-development deals, strategic investments, and entry to international markets.